Avantor, Inc. (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries. The company offers a wide range of products, including laboratory supplies, chemicals, and equipment. Avantor competes with other major players in the industry, such as Thermo Fisher Scientific and Merck KGaA.
On October 30, 2025, an analyst from UBS set a price target of $12 for AVTR, while the stock was priced at $11.58. This suggests a potential upside of approximately 3.63%. However, the stock has recently experienced a significant drop due to disappointing quarterly earnings, which has impacted investor sentiment.
Avantor's stock price fell sharply after the company reported earnings per share (EPS) of $0.22, missing the consensus estimate of $0.23. The stock, which had closed at $15.08, opened at $12.42 and last traded at $12.39. The trading volume was over 5.5 million shares, indicating heightened investor activity following the earnings announcement.
The company's revenue for the quarter was $1.62 billion, slightly below analyst expectations of $1.65 billion, and represented a 5.3% decrease compared to the same quarter last year. Despite a net margin of 10.31% and a return on equity of 11.39%, the earnings miss led to a reduction in the stock's price target by JPMorgan Chase and Co. from $17.00 to $14.00.
Currently, AVTR is priced at $11.58, reflecting a decrease of 23.21% from its previous close. The stock has fluctuated between a low of $11.54 and a high of $13.43 today. Over the past year, AVTR has reached a high of $23.71 and a low of $10.83. The company's market capitalization is approximately $7.89 billion, with a trading volume of 35.6 million shares on the NYSE.
